In today's IPKat, Darren Smyth analyses the decision in Regeneron Pharmaceuticals Inc, Bayer Pharma AG v Genentech Inc, a case which started as an action for a declaration of invalidity of Genentech’s patent, and declaration of non-infringement by a product that Regeneron planned to market called VEGF Trap Eye.